Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI

Market Cap	63.66B 55.99B 52.79B 48.16B 90.06B 6,111B 90.77B 633B 245B 3,110B 239B 234B 10,120B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 71.22B 67.13B 61.25B 115B 7,772B 115B 806B 312B 3,955B 304B 297B 12,872B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Sep. 17	Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications	CI
Sep. 15	Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies	CI
Sep. 01	Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist	CI
Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news: Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+2.68%	+2.56%	+59.32%	+114.68%	1,053B
JOHNSON & JOHNSON	+0.56%	+0.17%	+53.19%	+68.65%	652B
ABBVIE INC.	+0.02%	+0.42%	+20.51%	+73.58%	468B
ROCHE HOLDING AG	-0.34%	+1.57%	+42.12%	+45.22%	351B
NOVARTIS AG	+0.48%	+3.94%	+22.08%	+29.34%	273B
ASTRAZENECA PLC	+0.82%	+0.10%	+14.20%	+11.77%	254B
AMGEN INC.	-0.01%	+6.91%	+45.42%	+51.68%	220B
GILEAD SCIENCES, INC.	-1.11%	-0.80%	+31.69%	+99.56%	186B
NOVO NORDISK A/S	-0.03%	-10.26%	-30.03%	-60.35%	170B
Average	+0.35%	+0.30%	+28.72%	+48.24%	403.04B
Weighted average by Cap.	+0.89%	+1.00%	+39.13%	+67.95%

	2018	2019
Net sales	15.79B 13.89B 13.09B 11.94B 22.34B 1,515B 22.51B 157B 60.87B 771B 59.28B 57.99B 2,510B	16.09B 14.15B 13.34B 12.17B 22.76B 1,544B 22.94B 160B 62.04B 786B 60.41B 59.1B 2,558B
Net income	-5.1B -4.48B -4.23B -3.86B -7.21B -489B -7.27B -50.71B -19.65B -249B -19.13B -18.72B -810B	-5.27B -4.64B -4.37B -3.99B -7.46B -506B -7.52B -52.45B -20.32B -258B -19.79B -19.36B -838B
Net Debt	21.89B 19.25B 18.15B 16.56B 30.97B 2,101B 31.21B 218B 84.41B 1,069B 82.19B 80.41B 3,480B	17.3B 15.22B 14.35B 13.09B 24.48B 1,661B 24.67B 172B 66.72B 845B 64.97B 63.56B 2,751B

End-of-day quote NYSE
- ^USD	-